Epigen Biosciences entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease.
Novo Nordisk has licenced a technology to enable the generation of good manufacturing practice compliant human embryonic stem cell lines as well as the rights to further develop these into future regenerative medicine therapies.
Novo Nordisk, a Danish pharmaceutical company, will launch a production facility for full-cycle manufacturing of insulin in Kaluga region. Novo Nordisk insulin plant was commissioned in the Kaluga region in 2015.
Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.
Novo Nordisk announced the submission of a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA)
Novo Holdings announced the launch of an impact fund with a total budget of $165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.
Novo Nordisk today announced the headline results from the first phase 3a trial with oral semaglutide. First ever diabetes pill can change whole diabetes market replacing injection for blood sugar control.